Treatment options for recurrent primary CNS lymphoma
Primary CNS lymphoma (PCNSL) constitutes a rare extranodal variant of non-Hodgkin lymphoma (NHL) with an annual incidence of 0.45/100,000. Given the paucity of large prospective clinical trials, there is no consensus treatment for refractory or relapsed (r/r) PCNSL, and available strategies are larg...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 October 2022
|
| In: |
Current treatment options in oncology
Year: 2022, Jahrgang: 23, Heft: 11, Pages: 1548-1565 |
| ISSN: | 1534-6277 |
| DOI: | 10.1007/s11864-022-01016-5 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11864-022-01016-5
|
| Verfasserangaben: | Leon D. Kaulen, Joachim M. Baehring |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1827041277 | ||
| 003 | DE-627 | ||
| 005 | 20230428033650.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221214s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11864-022-01016-5 |2 doi | |
| 035 | |a (DE-627)1827041277 | ||
| 035 | |a (DE-599)KXP1827041277 | ||
| 035 | |a (OCoLC)1361670262 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kaulen, Leon D. |d 1992- |e VerfasserIn |0 (DE-588)1234159724 |0 (DE-627)1759034819 |4 aut | |
| 245 | 1 | 0 | |a Treatment options for recurrent primary CNS lymphoma |c Leon D. Kaulen, Joachim M. Baehring |
| 264 | 1 | |c 07 October 2022 | |
| 300 | |a 18 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.12.2022 | ||
| 520 | |a Primary CNS lymphoma (PCNSL) constitutes a rare extranodal variant of non-Hodgkin lymphoma (NHL) with an annual incidence of 0.45/100,000. Given the paucity of large prospective clinical trials, there is no consensus treatment for refractory or relapsed (r/r) PCNSL, and available strategies are largely based on retrospective analyses. Patient age, performance status, previously administered treatment, duration of response, and molecular characteristics guide selection of salvage therapy. Patients with a good performance status (KPS >70), particularly ≤65 years, and adequate organ function should be considered for salvage polychemotherapy. Based on its high overall response rate even in the relapsed setting, we choose high-dose (≥ 3.5g/m2) methotrexate (HD-MTX) based regimens, e.g., R-MPV (rituximab, HD-MTX, procarbazine, and vincristine), for remission re-induction as long as patients were sensitive to first line HD-MTX-based regimens, especially when duration of previous response was ≥ 1 year. Following successful remission induction, we choose myeloablative chemotherapy (e.g., thiotepa, busulfan, cyclophosphamide) and subsequent autologous stem cell transplant in curative intent whenever feasible. Alternatively, conventional chemotherapy regimens (for example, monthly HD-MTX) or low-dose whole-brain radiation therapy (WBRT) are selected for consolidation in non-transplant candidates in complete remission. In cases of HD-MTX refractory disease or contraindications, we use pemetrexed; temozolomide/rituximab; high-dose cytarabine; or whole brain radiation for remission induction. Clinical trial participation is considered as well. Emerging therapies for upfront or salvage therapy under ongoing investigation include bruton tyrosine kinase inhibition (e.g., ibrutinib), immunomodulatory drugs (e.g., lenalidomide), immune checkpoint inhibitors (ICI, e.g., nivolumab), and chimeric antigen receptor T (CAR-T) cell therapy. | ||
| 650 | 4 | |a CAR-T cell therapy | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Methotrexate | |
| 650 | 4 | |a Non-Hodgkin lymphoma | |
| 650 | 4 | |a Primary CNS lymphoma | |
| 650 | 4 | |a Recurrence | |
| 700 | 1 | |a Bähring, Joachim |e VerfasserIn |0 (DE-588)1084832941 |0 (DE-627)848754867 |0 (DE-576)456874968 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current treatment options in oncology |d Philadelphia, Pa. : Current Science, 2000 |g 23(2022), 11, Seite 1548-1565 |h Online-Ressource |w (DE-627)355398591 |w (DE-600)2090563-4 |w (DE-576)275076873 |x 1534-6277 |7 nnas |a Treatment options for recurrent primary CNS lymphoma |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:11 |g pages:1548-1565 |g extent:18 |a Treatment options for recurrent primary CNS lymphoma |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s11864-022-01016-5 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221214 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1234159724 |a Kaulen, Leon D. |m 1234159724:Kaulen, Leon D. |d 910000 |d 911100 |e 910000PK1234159724 |e 911100PK1234159724 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1827041277 |e 4231065780 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1827041277","language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 14.12.2022"],"person":[{"display":"Kaulen, Leon D.","roleDisplay":"VerfasserIn","role":"aut","family":"Kaulen","given":"Leon D."},{"display":"Bähring, Joachim","roleDisplay":"VerfasserIn","role":"aut","family":"Bähring","given":"Joachim"}],"title":[{"title":"Treatment options for recurrent primary CNS lymphoma","title_sort":"Treatment options for recurrent primary CNS lymphoma"}],"relHost":[{"origin":[{"publisherPlace":"Philadelphia, Pa.","publisher":"Current Science","dateIssuedKey":"2000","dateIssuedDisp":"2000-"}],"id":{"issn":["1534-6277"],"zdb":["2090563-4"],"eki":["355398591"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Current treatment options in oncology","title":"Current treatment options in oncology"}],"disp":"Treatment options for recurrent primary CNS lymphomaCurrent treatment options in oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 14.11.12"],"recId":"355398591","language":["eng"],"pubHistory":["1.2000 -"],"part":{"text":"23(2022), 11, Seite 1548-1565","volume":"23","extent":"18","year":"2022","issue":"11","pages":"1548-1565"}}],"physDesc":[{"extent":"18 S."}],"name":{"displayForm":["Leon D. Kaulen, Joachim M. Baehring"]},"id":{"eki":["1827041277"],"doi":["10.1007/s11864-022-01016-5"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"07 October 2022"}]} | ||
| SRT | |a KAULENLEONTREATMENTO0720 | ||